YahooSeptember 1, 2026 at 12:03 PM NY3 days ago

bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance

The company is evaluating an additional application for CyPath Lung that could complement CT imaging when monitoring lung cancer survivors for recurrence or new primary cancers. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) is advancing CyPath Lung for potential use in post-treatment lung cancer surveillance, expanding its focus beyond early detection.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Read at Source

Companies in This Story

TMOThermo Fisher Scientific Inc613.61− 0.78%

Companies in This Story

Related Stories